Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

07.12.22	Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes (PR Newswire)
06.12.22	Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology (PR Newswire)
01.12.22	Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases (PR Newswire)
01.12.22	Lilly Reports Positive Donanemab Data In Comparator Study In Early Symptomatic Alzheimer's Disease (RTTNews)
01.12.22	FDA Pulls Emergency Use Authorization For Lilly's COVID-19 Antibody Drug (RTTNews)
01.12.22	Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease (PR Newswire)
30.11.22	Lilly and Akouos Announce Expiration of Akouos Tender Offer (PR Newswire)
30.11.22	Form SC TO-T/A 59478 (RSS)
29.11.22	Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement (PR Newswire)
28.11.22	Form SC TO-T/A 59478 (RSS)
22.11.22	Form 4 59478 (RSS)
21.11.22	Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium (PR Newswire)
16.11.22	Lilly to Participate in Evercore ISI HealthCONx Conference (PR Newswire)
14.11.22	Form SC TO-T/A 59478 (RSS)
14.11.22	HUTCHMED Reports Mixed Results In Fruquintinib PhaseIII Study In Second-Line Gastric Cancer In China (RTTNews)
07.11.22	Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform (PR Newswire)
04.11.22	Lilly : Phase III Trial Shows Benefit Of Jardiance In Reducing Kidney Disease Progression In CKD (RTTNews)
04.11.22	Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease (PR Newswire)
03.11.22	Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting (PR Newswire)
03.11.22	Form 4 59478 (RSS)
01.11.22	Lilly Cuts FY22 Earnings Outlook Again - Update (RTTNews)
01.11.22	Eli Lilly And Co. Q3 Income Rises (RTTNews)
01.11.22	Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress (PR Newswire)
31.10.22	Form SC TO-T 59478 (RSS)
27.10.22	Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration (PR Newswire)
27.10.22	Form SC 13D 59478 (RSS)
19.10.22	Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement (PR Newswire)
18.10.22	Eli Lilly To Buy Akouos For Up To $610 Mln (RTTNews)
18.10.22	Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss (PR Newswire)
18.10.22	Written communication relating to an issuer or third party (RSS)
17.10.22	Lilly Declares Fourth-Quarter 2022 Dividend (PR Newswire)
10.10.22	Innovent Biologics : China Approves SNDA For CYRAMZA For Hepatocellular Carcinoma Treatment (RTTNews)
10.10.22	Innovent Biologics: China Oks Selpercatinib NDA For Treatment Of RET-driven Lung And Thyroid Cancers (RTTNews)
06.10.22	Eli Lilly Gets Fast Track Status For Its Tirzepatide To Treat Obesity (RTTNews)
06.10.22	Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities (PR Newswire)
28.09.22	Pre-market Movers: SILO, PRTA, BIIB, NXPL, ABOS… (RTTNews)
22.09.22	Lilly : FDA Approves Retevmo For Adult Patients With Locally Advanced Or Metastatic Solid Tumors (RTTNews)
22.09.22	FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type (PR Newswire)
08.09.22	Eli Lilly: Late-breaking Lebrikizumab Data Shows Long-lasting Results In Atopic Dermatitis (RTTNews)
08.09.22	Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials (PR Newswire)
08.09.22	Lilly Announces Details of Presentations at ESMO Congress 2022 (PR Newswire)
31.08.22	Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference (PR Newswire)
25.08.22	Lilly to Participate in Citi's 17th Annual BioPharma Conference (PR Newswire)
11.08.22	Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly (PR Newswire)
08.08.22	Eli Lilly Says New Formulation Of Taltz Injection Available Across US (RTTNews)
08.08.22	Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience (PR Newswire)
08.08.22	HUTCHMED Stock Up As Fruquintinib Global Phase III FRESCO-2 Study In CRC Meets Primary Goal (RTTNews)
04.08.22	Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results (PR Newswire)
04.08.22	Eli Lilly Reduces FY22 Earnings Guidance; Revenue Outlook Remains Unchanged (RTTNews)
04.08.22	Eli Lilly And Co. Profit Declines In Q2 (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20:03		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
18:01		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
17:58		Verluste in Europa: Euro STOXX 50 letztendlich leichter
17:58		Schwacher Handel: SMI schliesst mit Verlusten
16:01		Schwache Performance in New York: S&P 500 notiert zum Handelsstart im Minus
15:58		Handel in Zürich: SMI verbucht Verluste
15:58		Börse Frankfurt: So steht der LUS-DAX am Nachmittag
15:58		Zurückhaltung in Europa: Euro STOXX 50 präsentiert sich schwächer

20:03

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

18:01

Dow Jones aktuell: Dow Jones notiert am Mittag im Plus

17:58

Verluste in Europa: Euro STOXX 50 letztendlich leichter

17:58

Schwacher Handel: SMI schliesst mit Verlusten

16:01

Schwache Performance in New York: S&P 500 notiert zum Handelsstart im Minus

15:58

Handel in Zürich: SMI verbucht Verluste